CAPR:NSD-Capricor Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.09

Change

+0.03 (+0.98)%

Market Cap

USD 0.07B

Volume

0.05M

Avg Analyst Target

USD 18.00 (+482.52%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

Capricor Therapeutics Inc (CAPR) Stock Analysis:
Based on the Capricor Therapeutics Inc stock forecasts from 1 analysts, the average analyst target price for Capricor Therapeutics Inc is USD 18.00 over the next 12 months. Capricor Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Capricor Therapeutics Inc is Slightly Bearish, which is based on 3 positive signals and 5 negative signals. At the last closing, Capricor Therapeutics Inc’s stock price was USD 3.09. Capricor Therapeutics Inc’s stock price has changed by -0.96% over the past week, -6.08% over the past month and -14.64% over the last year.

About

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derive ...Read More

Company Website : https://www.capricor.com

Address : 10865 Road to the Cure, San Diego, CA, United States, 92121

Employees : 48

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 5.71

52 Week High : 6.22

Short Ratio : 3.28

52 Week Low : 2.56

Shorted Shares : 586,555

200 Day Moving Average : 3.83

Shorted Shares Previous Month : 645,825

50 Day Moving Average : 3.76

Shares Held By Insiders : 2.80%

Short Percentage : 2.48%

Shares Held by Institutions : 10.34%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-16 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

+9.49 (+1.47%)

 USD70.91B 8.97 6.88
VRTX Vertex Pharmaceuticals Incorpo..

+7.45 (+3.02%)

 USD63.10B 27.38 17.74
MRNA Moderna Inc

-1.65 (-1.20%)

 USD54.86B 4.87 2.41
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
BNTX BioNTech SE

-7.64 (-4.81%)

 USD38.60B 3.81 1.75
RPRX Royalty Pharma plc

+0.32 (+0.80%)

 USD26.93B 26.81 14.86
SGEN Seagen Inc

+6.91 (+5.09%)

 USD24.97B 55.02 44.86
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A
GMAB Genmab A/S

+0.06 (+0.20%)

 USD19.19B 46.16 5.06
ARGX argenx SE

-2.74 (-0.88%)

 USD16.75B N/A N/A

ETFs Containing CAPR

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.46% 94% A 92% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.46% 94% A 92% A-
Trailing 12 Months  
Capital Gain -20.16% 83% B 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -20.16% 83% B 49% F
Trailing 5 Years  
Capital Gain -66.85% 45% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -66.85% 45% F 14% F
Average Annual (5 Year Horizon)  
Capital Gain 9.88% 57% F 62% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.88% 56% F 59% F
Risk Return Profile  
Volatility (Standard Deviation) 112.19% 21% F 12% F
Risk Adjusted Return 8.81% 51% F 40% F
Market Capitalization 0.07B 37% F 24% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 4.20 57% F 86% B
Price/Book Ratio 2.29 37% F 36% F
Price / Cash Flow Ratio -4.43 65% D 70% C-
EV/EBITDA 0.03 96% A 98% A+
Management Effectiveness  
Return on Equity -67.23% 41% F 17% F
Return on Invested Capital -66.20% 38% F 15% F
Return on Assets -34.46% 31% F 10% F
Debt to Equity Ratio 10.76% 64% D 72% C-
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 3.28 63% D 48% F
Short Percent 2.48% 69% D+ 54% F
Beta 5.71 1% F 0% N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector